Login to Your Account



Syros shares sink on interim results for lead AML, MDS therapy

By Michael Fitzhugh
Staff Writer

Monday, December 11, 2017

Syros Pharmaceuticals shares lost nearly a third of their value Monday after investors learned that, by the end of October, just one out of 48 evaluable patients enrolled in an ongoing study of the company's lead gene control therapy, SY-1425, had achieved a complete response.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription